Form 8-K - Current report:
SEC Accession No. 0001827506-24-000061
Filing Date
2024-06-27
Accepted
2024-06-27 08:09:06
Documents
13
Period of Report
2024-06-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K trml-20240625.htm   iXBRL 8-K 30363
  Complete submission text file 0001827506-24-000061.txt   162838

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT trml-20240625.xsd EX-101.SCH 1919
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT trml-20240625_lab.xml EX-101.LAB 23449
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT trml-20240625_pre.xml EX-101.PRE 13593
16 EXTRACTED XBRL INSTANCE DOCUMENT trml-20240625_htm.xml XML 2915
Mailing Address 27 WEST 24TH STREET SUITE 702 NEW YORK NY 10010
Business Address 27 WEST 24TH STREET SUITE 702 NEW YORK NY 10010 646-481-9832
Tourmaline Bio, Inc. (Filer) CIK: 0001827506 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 241075417
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)